Investigational drugs for the treatment of binge eating disorder (BED): an update

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Fifth Edition. Washington DC: American Psychiatric Association. 2013.
   Google Scholar
• WHO. International classification of diseases 11th revision. 2018 [cited 2019 Apr 2]. Available from: https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f1673294767
   Google Scholar
• Davis C. The epidemiology and genetics of binge eating disorder (BED). CNS Spectr. 2015 Dec;20(6):522–529.
   PubMed Web of Science ®Google Scholar
• Fandino J, Moreira RO, Preissler C, et al. Impact of binge eating disorder in the psychopathological profile of obese women. Compr Psychiatry. 2010 Mar-Apr;51(2):110–114.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund PA, Chiu WT, et al. The prevalence and correlates of binge eating disorder in the world health organization world mental health surveys. Biol Psychiatry. 2013 May 1;73(9):904–914.
   PubMed Web of Science ®Google Scholar
• Guerdjikova AI, Mori N, Casuto LS, et al. Binge eating disorder. Psychiatr Clin North Am. 2017 Jun;40(2):255–266.
   PubMed Web of Science ®Google Scholar
• Mitchell JE. Medical comorbidity and medical complications associated with binge-eating disorder. Int J Eat Disord. 2016 Mar;49(3):319–323.
   PubMed Web of Science ®Google Scholar
• Udo T, Grilo CM. Psychiatric and medical correlates of DSM-5 eating disorders in a nationally representative sample of adults in the United States. Int J Eat Disord. 2019 Jan;52(1):42–50.
   PubMed Web of Science ®Google Scholar
• Mattos P, Saboya E, Ayrao V, et al. [Comorbid eating disorders in a Brazilian attention-deficit/hyperactivity disorder adult clinical sample]. Braz J Psychiatry. 2004 Dec;26(4):248–250.
   PubMedGoogle Scholar
• Agh T, Kovacs G, Pawaskar M, et al. Epidemiology, health-related quality of life and economic burden of binge eating disorder: a systematic literature review. Eat Weight Disord. 2015 Mar;20(1):1–12.
   PubMed Web of Science ®Google Scholar
• Kessler RM, Hutson PH, Herman BK, et al. The neurobiological basis of binge-eating disorder. Neurosci Biobehav Rev. 2016;63:223–238.
   PubMed Web of Science ®Google Scholar
• Kober H, Boswell RG. Potential psychological & neural mechanisms in binge eating disorder: implications for treatment. Clin Psychol Rev. 2018 Mar;60:32–44.
   PubMed Web of Science ®Google Scholar
• Smith DG, Robbins TW. The neurobiological underpinnings of obesity and binge eating: a rationale for adopting the food addiction model. Biol Psychiatry. 2013 May 1;73(9):804–810.
   PubMed Web of Science ®Google Scholar
• Schulte EM, Grilo CM, Gearhardt AN. Shared and unique mechanisms underlying binge eating disorder and addictive disorders. Clin Psychol Rev. 2016 Mar;44:125–139.
   PubMed Web of Science ®Google Scholar
• Hutson PH, Balodis IM, Potenza MN. Binge-eating disorder: clinical and therapeutic advances. Pharmacol Ther. 2018 Feb;182:15–27.
   PubMed Web of Science ®Google Scholar
• Amodeo G, Cuomo A, Bolognesi S, et al. Pharmacotherapeutic strategies for treating binge eating disorder. Evidence from clinical trials and implications for clinical practice. Expert Opin Pharmacother. 2019 Apr;20(6):679–690.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015 Mar;72(3):235–246.
   PubMed Web of Science ®Google Scholar
• Jain R, Jain S, Montano CB. Addressing diagnosis and treatment gaps in adults with attention-deficit/hyperactivity disorder. Prim Care Companion CNS Disord. 2017 Sep 7;19(5).
   PubMedGoogle Scholar
• McElroy SL. Pharmacologic treatments for binge-eating disorder. J Clin Psychiatry. 2017;78(Suppl 1):14–19.
   PubMedGoogle Scholar
• Giel KE, Teufel M, Junne F, et al. Food-related impulsivity in obesity and binge eating disorder-a systematic update of the evidence. Nutrients. 2017 Oct 27;9(11).
   PubMed Web of Science ®Google Scholar
• McElroy SL, Hudson J, Ferreira-Cornwell MC, et al. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: results of two pivotal phase 3 randomized controlled trials. Neuropsychopharmacology. 2016 Apr;41(5):1251–1260.
   PubMed Web of Science ®Google Scholar
• Hudson JI, McElroy SL, Ferreira-Cornwell MC, et al. Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2017 Sep 1;74(9):903–910.
   PubMed Web of Science ®Google Scholar
• Gasior M, Hudson J, Quintero J, et al. A phase 3, multicenter, open-label, 12-month extension safety and tolerability trial of lisdexamfetamine dimesylate in adults with binge eating disorder. J Clin Psychopharmacol. 2017 Jun;37(3):315–322.
   PubMed Web of Science ®Google Scholar
• Hopkins SC, Sunkaraneni S, Skende E, et al. Pharmacokinetics and exposure-response relationships of dasotraline in the treatment of attention-deficit/hyperactivity disorder in adults. Clin Drug Investig. 2016 Feb;36(2):137–146.
   PubMed Web of Science ®Google Scholar
• Koblan KS, Hopkins SC, Sarma K, et al. Dasotraline for the treatment of attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults. Neuropsychopharmacology. 2015 Nov;40(12):2745–2752.
   PubMed Web of Science ®Google Scholar
• Findling RL, Adler LA, Spencer TJ, et al. Dasotraline in children with attention-deficit/hyperactivity disorder: a six-week, placebo-controlled, fixed-dose trial. J Child Adolesc Psychopharmacol. 2019 Mar;29(2):80–89.
   PubMed Web of Science ®Google Scholar
• Navia BHJ, McElroy SL, Guerdjikova AI, et al. Dasotraline for the treatment of moderate to severe binge eating disorder in adults: results from a randomized, double-blind, placebo controlled study. CNS Spectr. 2018;2018:72–73.
   Google Scholar
• Citrome LL, Tsai J, Mandel M, et al. Effect of dasotraline on body weight in patients with binge-eating disorder. American Psychiatric Association 2019 Annual Meeting; 2019; San Francisco, CA, US.
   Google Scholar
• Tarver J, Daley D, Sayal K. Attention-deficit hyperactivity disorder (ADHD): an updated review of the essential facts. Child Care Health Dev. 2014 Nov;40(6):762–774.
   PubMed Web of Science ®Google Scholar
• Sinita E, Coghill D. The use of stimulant medications for non-core aspects of ADHD and in other disorders. Neuropharmacology. 2014 Dec;87:161–172.
   PubMed Web of Science ®Google Scholar
• Goldfield GS, Lorello C, Doucet E. Methylphenidate reduces energy intake and dietary fat intake in adults: a mechanism of reduced reinforcing value of food? Am J Clin Nutr. 2007 Aug;86(2):308–315.
   PubMed Web of Science ®Google Scholar
• Wang GJ, Geliebter A, Volkow ND, et al. Enhanced striatal dopamine release during food stimulation in binge eating disorder. Obesity (Silver Spring). 2011 Aug;19(8):1601–1608.
   PubMed Web of Science ®Google Scholar
• Quilty LC, Allen TA, Davis C, et al. A randomized comparison of long acting methylphenidate and cognitive behavioral therapy in the treatment of binge eating disorder. Psychiatry Res. 2019 Jan;17(273):467–474.
   Google Scholar
• Clemow DB, Bushe C, Mancini M, et al. A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities. Neuropsychiatr Dis Treat. 2017;13:357–371.
   PubMed Web of Science ®Google Scholar
• Gadde KM, Yonish GM, Wagner HR 2nd, et al. Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial. Int J Obes (Lond). 2006 Jul;30(7):1138–1142.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Guerdjikova A, Kotwal R, et al. Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry. 2007 Mar;68(3):390–398.
   PubMed Web of Science ®Google Scholar
• Fontenelle LF, Vı́tor Mendlowicz M, de Menezes GB, et al. Psychiatric comorbidity in a Brazilian sample of patients with binge-eating disorder. Psychiatry Res. 2003;119(1–2):189–194.
   PubMed Web of Science ®Google Scholar
• Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Fluoxetine bulimia nervosa collaborative study group. Arch Gen Psychiatry. 1992 Feb;49(2):139–147.
   PubMed Web of Science ®Google Scholar
• Lopresti AL, Drummond PD. Obesity and psychiatric disorders: commonalities in dysregulated biological pathways and their implications for treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:92–99.
   PubMed Web of Science ®Google Scholar
• Stefano SC, Bacaltchuk J, Blay SL, et al. Antidepressants in short-term treatment of binge eating disorder: systematic review and meta-analysis. Eat Behav. 2008 Apr;9(2):129–136.
   PubMedGoogle Scholar
• Guerdjikova AI, McElroy SL, Winstanley EL, et al. Duloxetine in the treatment of binge eating disorder with depressive disorders: a placebo-controlled trial. Int J Eat Disord. 2012 Mar;45(2):281–289.
   PubMed Web of Science ®Google Scholar
• Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002 Oct;10(10):1049–1056.
   PubMedGoogle Scholar
• White MA, Grilo CM. Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013 Apr;74(4):400–406.
   PubMed Web of Science ®Google Scholar
• Arnone D. Review of the use of Topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry. 2005 Feb 16;4(1):5.
   PubMedGoogle Scholar
• Antel J, Hebebrand J. Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. Handb Exp Pharmacol. 2012; 2012(209):433–466.
   Google Scholar
• Guglielmo R, Martinotti G, Quatrale M, et al. Topiramate in alcohol use disorders: review and update. CNS Drugs. 2015 May;29(5):383–395.
   PubMed Web of Science ®Google Scholar
• van Passel L, Arif H, Hirsch LJ. Topiramate for the treatment of epilepsy and other nervous system disorders. Expert Rev Neurother. 2006 Jan;6(1):19–31.
   PubMedGoogle Scholar
• Keck PE Jr., McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry. 2002;63(Suppl 4):3–11.
   PubMedGoogle Scholar
• McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry. 2003 Feb;160(2):255–261.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Hudson JI, Capece JA, et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry. 2007 May 1;61(9):1039–1048.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Shapira NA, Arnold LM, et al. Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J Clin Psychiatry. 2004 Nov;65(11):1463–1469.
   PubMed Web of Science ®Google Scholar
• Claudino AM, de Oliveira IR, Appolinario JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry. 2007 Sep;68(9):1324–1332.
   PubMed Web of Science ®Google Scholar
• Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230–240.
   PubMed Web of Science ®Google Scholar
• Buoli M, Grassi S, Ciappolino V, et al. The use of zonisamide for the treatment of psychiatric disorders: a systematic review. Clin Neuropharmacol. 2017 Mar/Apr;40(2):85–92.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Kotwal R, Guerdjikova AI, et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry. 2006 Dec;67(12):1897–1906.
   PubMed Web of Science ®Google Scholar
• Ng F, Hallam K, Lucas N, et al. The role of lamotrigine in the management of bipolar disorder. Neuropsychiatr Dis Treat. 2007 Aug;3(4):463–474.
   PubMedGoogle Scholar
• Merideth CH. A single-center, double-blind, placebo-controlled evaluation of lamotrigine in the treatment of obesity in adults. J Clin Psychiatry. 2006 Feb;67(2):258–262.
   PubMed Web of Science ®Google Scholar
• Guerdjikova AI, McElroy SL, Welge JA, et al. Lamotrigine in the treatment of binge-eating disorder with obesity: a randomized, placebo-controlled monotherapy trial. Int Clin Psychopharmacol. 2009 May;24(3):150–158.
   PubMed Web of Science ®Google Scholar
• Akbar M, Egli M, Cho YE, et al. Medications for alcohol use disorders: an overview. Pharmacol Ther. 2018;185:64–85.
   PubMed Web of Science ®Google Scholar
• Holt SR, Tobin DG. Pharmacotherapy for alcohol use disorder. Med Clin North Am. 2018 Jul;102(4):653–666.
   PubMed Web of Science ®Google Scholar
• Guardia D, Rolland B, Karila L, et al. GABAergic and glutamatergic modulation in binge eating: therapeutic approach. Curr Pharm Des. 2011;17(14):1396–1409.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Guerdjikova AI, Winstanley EL, et al. Acamprosate in the treatment of binge eating disorder: a placebo-controlled trial. Int J Eat Disord. 2011 Jan;44(1):81–90.
   PubMed Web of Science ®Google Scholar
• O’Malley SS, Todtenkopf MS, Du Y, et al. Effects of the opioid system modulator, samidorphan, on measures of alcohol consumption and patient-reported outcomes in adults with alcohol dependence. Alcohol Clin Exp Res. 2018 Oct;42(10):2011–2021.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Guerdjikova AI, Blom TJ, et al. A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder. Int J Eat Disord. 2013 Apr;46(3):239–245.
   PubMed Web of Science ®Google Scholar
• Cottone P, Sabino V, Steardo L, et al. Opioid-dependent anticipatory negative contrast and binge-like eating in rats with limited access to highly preferred food. Neuropsychopharmacology. 2008 Feb;33(3):524–535.
   PubMed Web of Science ®Google Scholar
• Heal DJ, Hallam M, Prow M, et al. Dopamine and mu-opioid receptor dysregulation in the brains of binge-eating female rats - possible relevance in the psychopathology and treatment of binge-eating disorder. J Psychopharmacol. 2017 Jun;31(6):770–783.
   PubMed Web of Science ®Google Scholar
• Martin-Blanco A, Patrizi B, Soler J, et al. Use of nalmefene in patients with comorbid borderline personality disorder and alcohol use disorder: a preliminary report. Int Clin Psychopharmacol. 2017 Jul;32(4):231–234.
   PubMed Web of Science ®Google Scholar
• Marazziti D, Piccinni A, Baroni S, et al. Effectiveness of nalmefene in binge eating disorder: a case report. J Clin Psychopharmacol. 2016 Feb;36(1):103–104.
   PubMed Web of Science ®Google Scholar
• Pomorska DK, do-Rego JC, do-Rego JL, et al. Opioid and cannabinoid system in food intake. Curr Pharm Des. 2016;22(10):1361–1370.
   PubMed Web of Science ®Google Scholar
• Giuliano C, Cottone P. The role of the opioid system in binge eating disorder. CNS Spectr. 2015 Dec;20(6):537–545.
   PubMed Web of Science ®Google Scholar
• Giuliano C, Robbins TW, Nathan PJ, et al. Inhibition of opioid transmission at the mu-opioid receptor prevents both food seeking and binge-like eating. Neuropsychopharmacology. 2012 Nov;37(12):2643–2652.
   PubMed Web of Science ®Google Scholar
• Ziauddeen H, Chamberlain SR, Nathan PJ, et al. Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects. Mol Psychiatry. 2013 Dec;18(12):1287–1293.
   PubMed Web of Science ®Google Scholar
• de Beaurepaire R, Sinclair JMA, Heydtmann M, et al. The use of baclofen as a treatment for alcohol use disorder: a clinical practice perspective. Front Psychiatry. 2018;9:708.
   PubMed Web of Science ®Google Scholar
• Broft AI, Spanos A, Corwin RL, et al. Baclofen for binge eating: an open-label trial. Int J Eat Disord. 2007 Dec;40(8):687–691.
   PubMed Web of Science ®Google Scholar
• Corwin RL, Boan J, Peters KF, et al. Baclofen reduces binge eating in a double-blind, placebo-controlled, crossover study. Behav Pharmacol. 2012 Sep;23(5–6):616–625.
   PubMed Web of Science ®Google Scholar
• de Beaurepaire R, Joussaume B, Rapp A, et al. Treatment of binge eating disorder with high-dose baclofen: a case series. J Clin Psychopharmacol. 2015 Jun;35(3):357–359.
   PubMed Web of Science ®Google Scholar
• Barth KS, Malcolm RJ. Disulfiram: an old therapeutic with new applications. CNS Neurol Disord Drug Targets. 2010 Mar;9(1):5–12.
   PubMed Web of Science ®Google Scholar
• Farci AM, Piras S, Murgia M, et al. Disulfiram for binge eating disorder: an open trail. Eat Behav. 2015;16:84–87.
   PubMed Web of Science ®Google Scholar
• Gadde KM, Martin CK, Berthoud HR, et al. Obesity: pathophysiology and management. J Am Coll Cardiol. 2018 Jan 2;71(1):69–84.
   PubMed Web of Science ®Google Scholar
• Nathan PJ, Bullmore ET. From taste hedonics to motivational drive: central mu-opioid receptors and binge-eating behaviour. Int J Neuropsychopharmacol. 2009 Aug;12(7):995–1008.
   PubMed Web of Science ®Google Scholar
• Appolinario JC, Bacaltchuk J, Sichieri R, et al. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry. 2003 Nov;60(11):1109–1116.
   PubMed Web of Science ®Google Scholar
• Milano W, Petrella C, Casella A, et al. Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study. Adv Ther. 2005 Jan-Feb;22(1):25–31.
   PubMed Web of Science ®Google Scholar
• Wilfley DE, Crow SJ, Hudson JI, et al. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. Am J Psychiatry. 2008 Jan;165(1):51–58.
   PubMed Web of Science ®Google Scholar
• Pilitsi E, Farr OM, Polyzos SA, et al. Pharmacotherapy of obesity: available medications and drugs under investigation. Metabolism. 2019;92:170–192.
   PubMed Web of Science ®Google Scholar
• Golay A, Laurent-Jaccard A, Habicht F, et al. Effect of orlistat in obese patients with binge eating disorder. Obes Res. 2005 Oct;13(10):1701–1708.
   PubMedGoogle Scholar
• Grilo CM, Masheb RM, Salant SL. Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 2005 May 15;57(10):1193–1201.
   PubMed Web of Science ®Google Scholar
• Grilo CM, White MA. Orlistat with behavioral weight loss for obesity with versus without binge eating disorder: randomized placebo-controlled trial at a community mental health center serving educationally and economically disadvantaged Latino/as. Behav Res Ther. 2013 Mar;51(3):167–175.
   PubMed Web of Science ®Google Scholar
• Heppner KM, Perez-Tilve D. GLP-1 based therapeutics: simultaneously combating T2DM and obesity. Front Neurosci. 2015;9:92.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Mori N, Guerdjikova AI, et al. Would glucagon-like peptide-1 receptor agonists have efficacy in binge eating disorder and bulimia nervosa? A review of the current literature. Med Hypotheses. 2018;111:90–93.
   PubMed Web of Science ®Google Scholar
• Saunders KH, Umashanker D, Igel LI, et al. Obesity Pharmacotherapy. Med Clin North Am. 2018 Jan;102(1):135–148.
   PubMed Web of Science ®Google Scholar
• Robert SA, Rohana AG, Shah SA, et al. Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - A pilot study. Obes Res Clin Pract. 2015 May-Jun;9(3):301–304.
   PubMed Web of Science ®Google Scholar
• Binge eating liraglutide intervention. [cited 2019 Jun 25]. Available from: https://ClinicalTrials.gov/show/NCT03279731
   Google Scholar
• Blumenthal SA, Pratt WE. d-Fenfluramine and lorcaserin inhibit the binge-like feeding induced by mu-opioid receptor stimulation of the nucleus accumbens in the rat. Neurosci Lett. 2018 Nov;20(687):43–48.
   Google Scholar
• Price AE, Brehm VD, Hommel JD, et al. Pimavanserin and lorcaserin attenuate measures of binge eating in male sprague-dawley rats. Front Pharmacol. 2018;9:1424.
   PubMed Web of Science ®Google Scholar
• Chao AM, Wadden TA, Pearl RL, et al. A randomized controlled trial of lorcaserin and lifestyle counselling for weight loss maintenance: changes in emotion- and stress-related eating, food cravings and appetite. Clin Obes. 2018 Dec;8(6):383–390.
   PubMed Web of Science ®Google Scholar
• Kramer CK, Leitao CB, Pinto LC, et al. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes Rev. 2011 May;12(5):e338–47.
   PubMed Web of Science ®Google Scholar
• Guerdjikova AI, Fitch A, McElroy SL. Successful treatment of binge eating disorder with combination phentermine/topiramate extended release. Prim Care Companion CNS Disord. 2015;17(2).
   PubMedGoogle Scholar
• Guerdjikova AI, Williams S, Blom TJ, et al. Combination phentermine-topiramate extended release for the treatment of binge eating disorder: an open-label, prospective study. Innov Clin Neurosci. 2018 Jun 1;15(5–6):17–21.
   PubMedGoogle Scholar
• Dalai SS, Adler S, Najarian T, et al. Study protocol and rationale for a randomized double-blinded crossover trial of phentermine-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa. Contemp Clin Trials. 2018;64:173–178.
   PubMed Web of Science ®Google Scholar
• Safer DLAS, Sethi S, Bentley J, et al. Randomized double-blinded crossover trial of phentermine-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa. American Psychiatric Association Annual Meeting 2018; 2018 May 5–9; New York, NY, US: American Psychiatric Association;. p. 641–642.
   Google Scholar
• Jones BJ, Bloom SR. The new era of drug therapy for obesity: the evidence and the expectations. Drugs. 2015 Jun;75(9):935–945.
   PubMed Web of Science ®Google Scholar
• Guerdjikova AI, Walsh B, Shan K, et al. Concurrent improvement in both binge eating and depressive symptoms with naltrexone/bupropion therapy in overweight or obese subjects with major depressive disorder in an open-label, uncontrolled study. Adv Ther. 2017 Oct;34(10):2307–2315.
   PubMed Web of Science ®Google Scholar
• Treatment of binge eating disorder in obesity: naltrexone/bupropion combination versus placebo. [cited 2019 Jun 25]. Available from: https://ClinicalTrials.gov/show/NCT02317744
   Google Scholar
• Behavioral and pharmacologic treatment of binge eating and obesity: specialist treatment. [cited 2019 Jun 25]. Available from: https://ClinicalTrials.gov/show/NCT03063606
   Google Scholar
• Behavioral and pharmacologic treatment of binge eating and obesity: maintenance therapy. [cited 2019 Jun 25]. Available from: https://ClinicalTrials.gov/show/NCT03047005
   Google Scholar
• Behavioral and pharmacologic treatment of binge eating and obesity: acute treatment. [cited 2019 Jun 25]. Available from: https://ClinicalTrials.gov/show/NCT03045341
   Google Scholar
• Cognitive-behavioral and pharmacologic (LDX) treatment of binge-eating disorder and obesity: medication change for non-responders. [cited 2019 Jun 25]. Available from: https://ClinicalTrials.gov/show/NCT03946111
   Google Scholar
• Efficacy and mechanisms of naltrexone+bupropion for binge eating disorder. [cited 2019 Jun 25]. Available from: https://ClinicalTrials.gov/show/NCT03539900
   Google Scholar
• Davidson JR, Abraham K, Connor KM, et al. Effectiveness of chromium in atypical depression: a placebo-controlled trial. Biol Psychiatry. 2003 Feb 1;53(3):261–264.
   PubMed Web of Science ®Google Scholar
• Martin J, Wang ZQ, Zhang XH, et al. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care. 2006 Aug;29(8):1826–1832.
   PubMed Web of Science ®Google Scholar
• Colotti G, Ilari A, Boffi A, et al. Metals and metal derivatives in medicine. Mini Rev Med Chem. 2013 Feb;13(2):211–221.
   PubMed Web of Science ®Google Scholar
• Brownley KA, Von Holle A, Hamer RM, et al. A double-blind, randomized pilot trial of chromium picolinate for binge eating disorder: results of the Binge Eating and Chromium (BEACh) study. J Psychosom Res. 2013 Jul;75(1):36–42.
   PubMed Web of Science ®Google Scholar
• Giel K, Zipfel S, Hallschmid M. Oxytocin and eating disorders: a narrative review on emerging findings and perspectives. Curr Neuropharmacol. 2018;16(8):1111–1121.
   PubMed Web of Science ®Google Scholar
• Leslie M, Leppanen J, Paloyelis Y, et al. The influence of oxytocin on eating behaviours and stress in women with bulimia nervosa and binge eating disorder. Mol Cell Endocrinol. 2019Nov;497:110354.
   PubMed Web of Science ®Google Scholar
• Gowda CR, Lundt LP. Mechanism of action of narcolepsy medications. CNS Spectr. 2014 Dec;19(Suppl 1):25–33. quiz 25-7, 34.
   PubMedGoogle Scholar
• McElroy SL, Guerdjikova AI, Mori N, et al. Armodafinil in binge eating disorder: a randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2015 Jul;30(4):209–215.
   PubMed Web of Science ®Google Scholar
• Abad VC. An evaluation of sodium oxybate as a treatment option for narcolepsy. Expert Opin Pharmacother. 2019 May;28:1–11.
   Google Scholar
• McElroy SL, Guerdjikova AI, Winstanley EL, et al. Sodium oxybate in the treatment of binge eating disorder: an open-label, prospective study. Int J Eat Disord. 2011 Apr;44(3):262–268.
   PubMed Web of Science ®Google Scholar
• Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis. PLoS One. 2015;10(4):e0123289.
   PubMed Web of Science ®Google Scholar
• Brennan BP, Roberts JL, Fogarty KV, et al. Memantine in the treatment of binge eating disorder: an open-label, prospective trial. Int J Eat Disord. 2008 Sep;41(6):520–526.
   PubMed Web of Science ®Google Scholar
• R NBHJMSGADLSKHSKKLAG. Dasotraline for the treatment of moderate-to-severe binge eating disorder in adults: results from a randomized, double-blind, placebo-controlled study. Poster presented at Psych Congress 2018; 2018 Oct 25–28; Orlando, FL.
   Google Scholar
• Novelle MG, Dieguez C. Food addiction and binge eating: lessons learned from animal models. Nutrients. 2018 Jan 11;10(1). pii:E71.
   PubMed Web of Science ®Google Scholar
• Vyvanse (lisdexamphetamine dismesylate) [package insert]. Lexington, MA: Shire US, Inc.; January 2017.
   Google Scholar
• Blom TJGuerdjikova AI, Mc elroy sl. Placebo Reponse and Cessation in Binge Eating Disorder: A Pooled Analysis Of Two Randomized Paralled-group Clinical Trials. Eur Eat Disord Rev. 2019 Jan;23(1):86–8.
   Google Scholar
• Blom TJ, Guerdjikova AIMori N, et al. Placebo cessation in binge eating disorder: Effect on anthropometric, cardiovascular, and metabolic variables. Eur Eat Disord Rev 2015 Jan;23(1):86-8.
   PubMed Web of Science ®Google Scholar
• Kalaria SN, McElroy SLGobburu J, An innovative disease-drug-trial framework to guide binge eating disorder drug development: A case study for topiramate. Clin Transl Sci. 2019 Aug.
   PubMed Web of Science ®Google Scholar